Romiplostim N01 Plus ATRA for Low Platelets After Gut Cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of two medicines (Romiplostim N01 and ATRA) to raise dangerously low platelet counts that sometimes persist after chemotherapy for digestive cancers. If your platelets stay low even after previous platelet-raising treatments, this study may help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your digestive or gut cancer (stomach, pancreas, colon, etc.) must be completely gone and you must have finished cancer treatment at least 12 weeks ago
- Your platelet count must be very low (below 30,000) or require blood transfusions to stay safe
- Low platelets must have persisted since your last chemotherapy without clear improvement on their own
- You must have tried at least one other platelet-raising medicine for at least 2 weeks without success
- Recent bone marrow test (within 1 year) must show no cancer cells and normal or high platelet-producing cells
- You cannot have other blood disorders, active cancer, severe organ disease, or active serious infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
This trial tests a drug called romiplostim to prevent low platelet counts (a condition that raises bleeding risk) caused by chemotherapy in people with breast cancer. If you qualify, you may receive this drug to help keep your platelets at a safer level during future treatments.
This study tests a new medication called romiplostim that may help raise your platelet count when it drops too low after radiation therapy. If you have a solid tumor and your platelets are below 75,000, this treatment could help you recover and avoid complications.
Hear when a new Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.